文献速递骨软组织肉瘤与黑色素瘤

晚期黑色素瘤抗PD-1治疗患者活检主要病理缓解(MPRbx):早期治疗中反应生物标志物的证据

Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response.
PubMed 文献 · Ann Oncol · 2019-01-01

研究在发现队列16例晚期黑色素瘤患者中识别抗PD-1治疗后免疫相关病理缓解(irPR)特征并构建irPR评分(0-3分,3分即MPRbx,残留存活肿瘤≤10%),随后在CA209-038纳武利尤单抗单药治疗队列的51例治疗中4周活检标本中验证。验证队列中irPR评分升高与客观缓解相关(P=0.009),MPRbx与总生存改善相关(n=51;HR 0.13;95%CI 0.054-0.31,P=0.015)。

要点

  • irPR评分基于H&E染色活检中免疫激活与创伤愈合/组织修复特征构建,评分0-3分,3分定义为MPRbx(残留存活肿瘤≤10%)。
  • 验证队列中irPR评分与客观缓解相关(P=0.009),MPRbx与总生存改善相关(n=51;HR 0.13;95%CI 0.054-0.31,P=0.015)。
  • 16例疾病稳定患者中8例(50%)显示irPR特征,其中2例为MPRbx,提示部分患者4周治疗中活检病理与影像学特征不一致。

核心结论

  • 晚期黑色素瘤患者抗PD-1治疗后常规H&E染色活检中的免疫介导肿瘤消退特征与客观缓解及总生存相关。
  • 治疗中活检可能对影像学疾病稳定患者的治疗决策特别有临床价值。
  • 该方法费用低、操作直接且广泛可用。

研究设计与样本

  • 发现队列:16例晚期黑色素瘤患者抗PD-1治疗前及治疗中标本,在H&E染色切片上识别免疫相关病理缓解特征并构建irPR评分。
  • 验证队列:CA209-038研究(NCT01621490)纳武利尤单抗单药治疗臂入组黑色素瘤患者,前瞻性收集治疗前及治疗中活检(治疗中4周时间点n=51),检验irPR评分与RECIST1.1客观缓解及总生存的关联。

主要发现

  • 发现队列中缓解者标本较非缓解者具有免疫激活特征(中高密度肿瘤浸润淋巴细胞、浆细胞)和创伤愈合/组织修复特征(新生血管化、增殖性纤维化),每个特征P≤0.021。
  • 验证队列中irPR评分升高与客观缓解相关(P=0.009)。
  • 验证队列中MPRbx与总生存改善相关(n=51;HR 0.13;95%CI 0.054-0.31,P=0.015)。
  • 肿瘤坏死及治疗前组织学特征均与缓解无关。
  • 16例疾病稳定患者中8例(50%)显示irPR特征,其中2例为MPRbx,提示部分患者4周治疗中时间点病理与影像学特征不一致。

关键数值与推荐

  • irPR评分范围0-3分:0分=无irPR特征,3分=活检主要病理缓解(MPRbx,残留存活肿瘤≤10%)。
  • 验证队列中irPR评分与客观缓解相关(P=0.009)。
  • 验证队列中MPRbx与总生存相关(n=51;HR 0.13;95%CI 0.054-0.31,P=0.015)。

临床怎么用

  • 原文结论指出治疗中活检可能对影像学疾病稳定患者的治疗决策特别有临床价值。
  • 原文结论指出该方法费用低、操作直接且广泛可用。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: With increasing anti-PD-1 therapy use in patients with melanoma and other tumor types, there is interest in developing early on-treatment biomarkers that correlate with long-term patient outcome. An understanding of the pathologic features of immune-mediated tumor regression is key in this endeavor. MATERIALS AND METHODS: Histologic features of immune-related pathologic response (irPR) following anti-PD-1 therapy were identified on hematoxylin and eosin (H&E)-stained slides in a discovery cohort of pre- and on-treatment specimens from n = 16 patients with advanced melanoma. These features were used to generate an irPR score [from 0 = no irPR features to 3 = major pathologic response on biopsy (MPRbx, ≤10% residual viable tumor)]. This scoring system was then tested for an association with objective response by RECIST1.1 and overall survival in a prospectively collected validation cohort of pre- and on-treatment biopsies (n = 51 on-treatment at 4-week timepoint) from melanoma patients enrolled on the nivolumab monotherapy arm of CA209-038 (NCT01621490). RESULTS: Specimens from responders in the discovery cohort had features of immune-activation (moderate-high TIL densities, plasma cells) and wound-healing/tissue repair (neovascularization, proliferative fibrosis) compared to nonresponders, (P ≤ 0.021, for each feature). In the validation cohort, increasing irPR score associated with objective response (P = 0.009) and MPRbx associated with increased overall survival (n = 51; HR 0.13; 95%CI, 0.054-0.31, P = 0.015). Neither tumoral necrosis nor pretreatment histologic features were associated with response. Eight of 16 (50%) of patients with stable disease showed irPR features, two of which were MPRbx, indicating a disconnect between pathologic and radiographic features at the 4-week on-therapy timepoint for some patients. CONCLUSIONS: Features of immune-mediated tumor regression on routine H&E-stained biopsy slides from patients with advanced melanoma correlate with objective response to anti-PD-1 and overall survival. An on-therapy biopsy may be particularly clinically useful for informing treatment decisions in patients with radiographic stable disease. This approach is inexpensive, straightforward, and widely available.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Stein JE, Soni A, Danilova L, et al. Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response. Ann Oncol. 2019. PMID: 30689736. doi:10.1093/annonc/mdz019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。